Top gappers on : STAK, SHFS and BHVN
Market Analysis
BHVN: The FDA Accepted the Resubmission. The High Came at 7:51 a.m.
Biohaven gapped 37% after the FDA accepted its troriluzole resubmission. The high came at 7:51 a.m. and it closed 20% below it. What the 8-K said.
Rank 3BHVNBiohaven Ltd.
- Opening gap
- +37.02%
- Day
- +25.02%
- HOD (ET)
- 18.3907:51 ET
- Est. turnover
- $476.7M
- Gap-ups (≥1M shares)
- 634
Data to the close of October 22, 2026 (ET). Sources checked October 23.
Biohaven filed a short 8-K at 7:00 a.m. on Thursday. By 7:51 the stock was up 56.5%. That was the high of the day. When the regular session opened two hours later, BHVN was already 12.5% below it, and it closed up 25.0% — a strong day on paper, and a hard one for anyone who bought the open.
The filing is worth reading closely, because what it says is narrower than the move.
The 8-K was accepted by the SEC at 7:00:07 ET. It reports one thing: the FDA has accepted for review Biohaven's resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia (SCA).
Three details matter:
It does not say the drug was approved, and it does not describe what the FDA thinks of the new data. The company's own cautionary note says the goal date "does not assure that the FDA will act by that date or approve the NDA."
So the news was a scheduling event: the application is back in review, with a date and a public panel ahead.
